Bioprocess Monitoring

Global Bioprocess Monitoring Market to Reach US$6.8 Billion by 2030

The global market for Bioprocess Monitoring estimated at US$4.0 Billion in the year 2024, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 9.0% CAGR

The Bioprocess Monitoring market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Bioprocess Monitoring Market – Key Trends & Drivers Summarized

Why Is Bioprocess Monitoring Essential for the Future of Biopharmaceutical Manufacturing?

Bioprocess monitoring has become a critical component in biopharmaceutical production, ensuring efficiency, product quality, and regulatory compliance in drug manufacturing. As the demand for biologics, including monoclonal antibodies, vaccines, cell therapies, and gene therapies, continues to rise, precise real-time monitoring of bioprocesses is essential for optimizing yields and reducing batch failures. Bioprocess monitoring involves tracking critical parameters such as pH, dissolved oxygen, temperature, glucose levels, cell viability, and metabolite concentrations, enabling manufacturers to maintain consistency in bioproduction.

With the transition toward single-use bioprocessing systems and continuous manufacturing models, real-time data acquisition and process control have become increasingly important. Regulatory bodies such as the FDA and EMA are emphasizing process analytical technology (PAT) and Quality by Design (QbD) approaches, driving the adoption of advanced bioprocess monitoring solutions. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) into bioprocess monitoring is transforming the industry by enabling predictive analytics and automated process optimization. As biopharma companies seek to enhance efficiency, reduce operational costs, and accelerate time-to-market, the role of bioprocess monitoring in ensuring consistent product quality and regulatory compliance continues to grow.

How Are Technological Innovations Enhancing Bioprocess Monitoring?

Rapid advancements in sensor technology, automation, and data analytics are revolutionizing bioprocess monitoring, allowing for real-time control of complex biological systems. One of the most significant innovations in this space is the development of miniaturized, non-invasive, and in-line sensors that provide continuous monitoring of bioreactors without disrupting the cell culture environment. These advanced sensors, including Raman spectroscopy, near-infrared (NIR) spectroscopy, and biosensors, enable precise measurement of key bioprocess parameters with minimal sample handling, reducing contamination risks and improving process efficiency.

Another breakthrough in bioprocess monitoring is the integration of AI-driven predictive analytics, which allows manufacturers to anticipate deviations and optimize process conditions before issues arise. Cloud-based monitoring platforms and digital twins are also transforming biomanufacturing, enabling remote access to real-time process data and virtual modeling of bioreactors for enhanced decision-making. Additionally, automation and robotics are improving process consistency by eliminating manual interventions, reducing variability, and increasing throughput. The expansion of single-use bioprocessing technologies has further driven the need for real-time monitoring solutions, ensuring that disposable systems maintain reproducibility and compliance in large-scale bioproduction.

Which Market Trends Are Driving Growth in the Bioprocess Monitoring Industry?

The growing adoption of biologics, personalized medicine, and biosimilars is one of the most significant trends driving the bioprocess monitoring market. As pharmaceutical companies shift toward the production of high-value biologics and cell-based therapies, maintaining precise control over bioprocess conditions has become increasingly important to ensure therapeutic efficacy and regulatory approval. Additionally, the rise of single-use bioprocessing systems and modular manufacturing facilities has fueled demand for portable and disposable monitoring solutions that integrate seamlessly with flexible production workflows.

Another key trend shaping the market is the increasing reliance on data-driven biomanufacturing. Real-time analytics, cloud computing, and AI-powered process control are transforming how biopharma companies manage production, enabling proactive decision-making and reducing downtime. The emergence of continuous bioprocessing is further accelerating demand for in-line monitoring technologies that can track cell growth, metabolic activity, and process deviations in real-time. Additionally, the push for cost-effective biomanufacturing in emerging markets is driving investments in advanced monitoring solutions to improve scalability and production efficiency. As the pharmaceutical industry embraces digitalization and automation, bioprocess monitoring is becoming a fundamental enabler of next-generation biomanufacturing.

What Are the Key Growth Drivers Shaping the Future of the Bioprocess Monitoring Market?

The growth in the bioprocess monitoring market is driven by several key factors, including the increasing demand for biologics, advancements in sensor technology, and the adoption of Industry 4.0 practices in biomanufacturing. One of the primary growth drivers is the expanding pipeline of monoclonal antibodies, gene therapies, and recombinant proteins, which require precise process control to ensure batch-to-batch consistency and regulatory compliance. As regulatory agencies impose stricter quality standards, pharmaceutical companies are investing heavily in bioprocess monitoring solutions to maintain Good Manufacturing Practices (GMP) and prevent product failures.

Another crucial driver shaping the market is the rapid expansion of contract development and manufacturing organizations (CDMOs), which are leveraging advanced bioprocess monitoring to enhance production efficiency and meet the growing demand for outsourced biologics manufacturing. The integration of AI, big data analytics, and digital twins in bioprocessing is also accelerating market growth, providing manufacturers with real-time insights into process optimization and predictive maintenance. Furthermore, the increasing adoption of continuous manufacturing is driving demand for robust, in-line monitoring solutions that enable seamless process control and higher production yields. As the pharmaceutical industry continues to innovate and optimize biomanufacturing processes, the demand for bioprocess monitoring technologies will continue to rise, shaping the future of precision-driven biologics production.

SCOPE OF STUDY:

The report analyzes the Bioprocess Monitoring market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Reagents and Kits, Instruments, Software); Application (Host Cell Residual DNA/Protein Quantitation Application, Mycoplasma Detection Application, Viral Titer Determination Application, Adventitious Virus Testing Application, Other Applications); End-Use (Pharmaceutical and Biotechnology Companies End-Use, CROs and CMOs End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• Agilent Technologies
• Applied Biological Materials Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne
• Bruker
• Danaher Corporation
• Eppendorf AG
• F. Hoffmann-La Roche AG
• GE Healthcare
• Hamilton Company
• Lonza Group Ltd.
• Maravai Life Sciences
• Nova Biomedical
• PerkinElmer
• Qiagen NV
• Sartorius AG
• Shimadzu Corporation
• Thermo Fisher Scientific, Inc.
• Waters Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.